The Conversation (0)
GT Biopharma announced the US Food and Drug Administration accepted the transfer of the IND 136205.
GT Biopharma (OTCQB:GTBP) announced the US Food and Drug Administration accepted the transfer of the INDÂ 136205.
As quoted in the press release:
The FDA has accepted the transfer of IND 136205 Change of Sponsor from the University of Minnesota to GT Biopharma for a commercial IND of OXS-3550 (anti-CD16-IL-15-anti-CD33); a first of its kind, single-chain, tri-specific NK cell engager (TriKE).
OXS-3550 TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. As demonstrated in non-clinical models, this targeted immunotherapy directs immune cells to kill cancer cells while diminishing drug-related toxicity.
Several months ago, the GT Biopharma TriKE platform technology received funding from the University of Minnesota’s National Institution of Health (NIH) REACH award. This award is given by the NIH to support technology that is promising for commercial success.